Log In
Print
BCIQ
Print
Print this Print this
 

CEP-37440

  Manage Alerts
Collapse Summary General Information
Company Teva Pharmaceutical Industries Ltd.
DescriptionAnaplastic lymphoma kinase (ALK) and focal adhesion kinase (FAK) inhibitor
Molecular Target Anaplastic lymphoma kinase (ALK) ; Focal adhesion kinase (FAK)
Mechanism of ActionAnaplastic lymphoma kinase (ALK) inhibitor; Focal adhesion kinase (FAK) inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat advanced or metastatic solid tumors
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$28.4M

$1.4M

$27.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today